Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate.
about
HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loadsThe spread, treatment, and prevention of HIV-1: evolution of a global pandemicThe Antibody Response against HIV-1Structural Definition of an Antibody-Dependent Cellular Cytotoxicity Response Implicated in Reduced Risk for HIV-1 InfectionDiverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 bindingNew concepts in HIV-1 vaccine developmentMonoclonal antibodies to the V2 domain of MN-rgp120: fine mapping of epitopes and inhibition of α4β7 bindingVaccine-Elicited Mucosal and Systemic Antibody Responses Are Associated with Reduced Simian Immunodeficiency Viremia in Infant Rhesus MacaquesImmune-correlates analysis of an HIV-1 vaccine efficacy trialSurvivors Remorse: antibody-mediated protection against HIV-1.Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design.Antibody-Mediated Fcγ Receptor-Based Mechanisms of HIV Inhibition: Recent Findings and New Vaccination StrategiesHuman immunodeficiency virus vaccine trialsWeighted likelihood method for grouped survival data in case-cohort studies with application to HIV vaccine trials.HIV-1 vaccines: challenges and new perspectivesNovel directions in HIV-1 vaccines revealed from clinical trialsMulti-Parameter Exploration of HIV-1 Virus-Like Particles as Neutralizing Antibody Immunogens in Guinea Pigs, Rabbits and MacaquesAdvancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates.High affinity allele for the gene of FCGR3A is risk factor for HIV infection and progressionRole of humoral immunity in host defense against HIV.Fc receptor-mediated antiviral antibodies.New paradigms for functional HIV-specific nonneutralizing antibodiesEpitope target structures of Fc-mediated effector function during HIV-1 acquisition.HIV-1 envelope proteins and V1/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.The role of Fc receptors in HIV infection and vaccine efficacy.Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccinesFCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques.Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.The role of natural killer (NK) cells and NK cell receptor polymorphisms in the assessment of HIV-1 neutralizationInnate immunity against HIV: a priority target for HIV prevention researchRapid high-level production of functional HIV broadly neutralizing monoclonal antibodies in transient plant expression systemsB cell responses to HIV-1 infection and vaccination: pathways to preventing infection.Antibody-dependent cell-mediated viral inhibition emerges after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys coincident with gp140-binding antibodies and is effective against neutralization-resistant viruses.Is developing an HIV-1 vaccine possible?Scaffold functions of 14-3-3 adaptors in B cell immunoglobulin class switch DNA recombination.Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen.Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infectionProspects for engineering HIV-specific antibodies for enhanced effector function and half-life.
P2860
Q21131399-B57EFAEE-352E-427F-8683-E1433FF32DDAQ22241890-F7325274-2D85-4A08-B9E0-5883988DAFD5Q27000889-4A977C6F-CAD8-499F-90EC-077AE8DC022FQ27640572-38582543-C50B-4056-AAD6-D0A7DCBFF58CQ27675486-BF117C44-7CFA-468A-A928-4195D03C065EQ28067027-D0DD06D9-9878-4083-A114-1AEC2A7F7972Q28728517-03DC2C53-0BDA-42E7-8E36-2B530B8DA6EDQ28830298-5E096FE0-882A-4886-8C55-CEA6DB628F18Q29617377-E6461B53-B398-472F-B698-A39C206BF1DFQ30238730-15C00744-6BAF-4276-9F6B-14BBBE7A7740Q30375160-8D3ED132-BAE7-4609-A114-864A3BAA9CECQ30408097-BC9AA0F6-7641-4F93-91E4-4FE94BE5A28FQ30424366-9AAFEC25-AF46-4B66-A39F-21D586F91203Q33386994-B853331F-026F-440F-B30B-10C1EBB8B2CEQ33577972-46D41DCF-BCE6-4D20-BF17-C76B2A9F7E43Q33645528-E1F9AC02-AB95-4C43-A02B-9C05B3F22377Q33683203-DE66167C-23A2-49BD-AA3E-A9562D38061FQ33742529-1B54C9D1-9FFD-4140-AF0A-C2917A389573Q33781067-AB6CE21E-7B83-4971-8C68-26E29831F261Q33898131-5810EF8B-2EC3-4D86-9A72-A687E7FBB3E8Q33899181-5DCD43C7-8354-4CE1-8364-1E1BDBC7E1D4Q33900595-759D41BC-DE7F-4E3C-A3C2-2E8B6F66D3B7Q33924272-A6CFFDAA-3A07-4849-A0DE-B4EFC7C3FD51Q33947008-34BBE79F-F347-4C01-851F-379B2E98DD69Q33966586-74672241-443E-45BB-BA5D-554C338EE6CEQ33997395-60DCF090-43F3-4429-8281-E560B0B530FBQ34057711-E193E6B7-BCA7-468D-9E08-BE77584F7408Q34117524-BDC6071C-DE6D-4655-A498-710479344EAAQ34185625-3F73B157-35DD-4516-BF66-223D93090679Q34204047-54BF08B9-2A61-4261-93F8-2531C703D95AQ34234905-5E525ACE-83B1-474D-8D38-A0D6DE24CF1CQ34243462-B30E0709-4298-4524-9C10-5F355331C039Q34637663-37411063-43F1-41C2-8906-03FD13F72B84Q34645502-9EEE99CF-5B3F-499C-A393-A66D9D5C4713Q34982646-582F0D3D-36A9-4483-B5C0-E75F57A4E353Q35043547-ABCC628A-F0AE-4219-9913-B1BE543F4E27Q35055116-4868610F-25E2-49D1-94CB-1E0A694EB2FBQ35192726-6501B105-9D46-42BF-AC57-EFAC280386BAQ35363127-3CAD1335-4E8A-4E6A-B62D-5354C53F6595Q35569901-D61C75BB-1CAE-405E-9564-76306F0B06CA
P2860
Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Recombinant gp120 vaccine-indu ...... rsely with HIV infection rate.
@en
Recombinant gp120 vaccine-indu ...... rsely with HIV infection rate.
@nl
type
label
Recombinant gp120 vaccine-indu ...... rsely with HIV infection rate.
@en
Recombinant gp120 vaccine-indu ...... rsely with HIV infection rate.
@nl
prefLabel
Recombinant gp120 vaccine-indu ...... rsely with HIV infection rate.
@en
Recombinant gp120 vaccine-indu ...... rsely with HIV infection rate.
@nl
P2093
P1476
Recombinant gp120 vaccine-indu ...... rsely with HIV infection rate.
@en
P2093
Donald N Forthal
Gary Landucci
Peter B Gilbert
P304
P356
10.4049/JIMMUNOL.178.10.6596
P407
P577
2007-05-01T00:00:00Z